In vivo thrombolytic studies in stumptailed monkeys indicated that pentoxifylline potentiates thrombolysis induced by urokinase activated human plasmin. Pentoxifylline as well as prostaglandin E1 released plasminogen activators and activated the fibrinolysin system. From this point of view pentoxifylline and prostaglandin E1 synergized with each other. Pentoxifylline potentiated the thrombolytic effect of prostaglandin E1 in vivo.
Get full access to this article
View all access options for this article.
References
1.
Ehrly AM: The effect of pentoxifylline on the deformability of erythrocytes and on muscular oxygen pressure in patients with chronic arterial disease . J Med10:331, 1979.
2.
Muller R.: Pentoxifylline — a biomedical profile. J Med10:307, 1979.
3.
Lehrach F., Muller R.: Ergebnisse der Klinischen Prüfung des Vasotherapeuticums 3, 7-Dimethyl-1-(5-oxohexyl)-xanthine (B1.191). Arzneim Forsch21:1171-1174, 1971 .
4.
Angelkort B. : Influence of pentoxifylline (Trental 400) on microcirculation. Poststenotic blood pressure and walking capacity in patients with chronic occlusive arterial disease. IRCS Med Sci5:370, 1977.
5.
Baumann JC: Doppler ultrasonic blood pressure measurements in limbs with occlusive arterial disease and in normal lower extremities under treatment with pentoxifylline . IRCS Med Sci4:93, 1976.
6.
Bollinger A. , Frei C.: Double-blind study of pentoxifylline against placebo in patients with intermittent claudication. PharmatherapeuticaI:557, 1977.
7.
Ehrly AM, Schroeder W., Dannhof S.: The effect of pentoxifylline on the oxygen pressure of ischemic muscle tissue in patients with chronic arterial occlusions. IRCS Med Sci5:411, 1977.
8.
Heidrich H., Witt D., Witt E.: Plethysmographic studies in the influence of intra-venous long term therapy with pentoxifylline in arterial occlusive disease. IRCS Med Sci5:487, 1977.
9.
Jovanovic UJ : Statistical evaluation of polygraphic investigations of pentoxifylline. J Int Med Res4:211, 1976.
10.
Lusov VA, Belousov JB, Sidelmann AA, et al: The treatment of peripheral atherosclerosis with pentoxifylline . Pharmatherapeutica2:123, 1978.
11.
Schubotz R. : Double-blind trial of pentoxifylline in diabetics with peripheral vascular disorders. Pharmatherapeutica1:172, 1976.
12.
Porter JM, Cutler BS, Lee BY, et al: Pentoxifylline efficacy in the treatment of intermittent claudication: Multicenter controlled double-blind trial with objective assessment of chronic occlusive arterial disease patients. Am Heart J104:66, 1982.
13.
Gastpar H., Ambrus JL, Ambrus CM, et al: Study of platelet aggregation in vivo III. Effect of pentoxifylline . J Med8:191, 1977.
14.
Muller R., Lehrach F.: Haemorheological role of platelet aggregation and hypercoagulability in microcirculation: Therapeutic approach with pentoxifylline. In: Disorders of Blood Flow. New Therapeutic Aspects, ed. by Manrique RV, Muller R.Amsterdam, Oxford, Princeton,Excerpta Medica, 1981 , p. 43.
15.
Stefanovich V., et al: On the influence of pentoxifylline on the permeability of rat erythrocytes for methyl-0-glucose. Arzneimittel-Forsch29:757, 1979.
16.
Takamatsu S. , Sato K., Takamatsu M., et al: Changes in haematological and blood chemical parameters after treatment of aged arteriosclerotic patients with pentoxifylline. Pharmatherapeutica2:165, 1979.
17.
Jarrett Pem , Moreland M., Browse NL: The effect of pentoxifylline (Trental) on fibrinolytic activity and fibrinogen levels. Curr Med Opin4:492, 1977.
18.
Satewachin II, Iljin VN, Schestakov VA, et al: The use of pentoxifylline in a combined regimen for the prevention of re-thrombosis in major blood vessels . Pharmatherapeutica2 (Supp 1):109, 1978.
19.
Turpie Agg, Forbes CD, McNichol GP: Idiopathic gangrene in African children. Brit Med J23:646, 1967.
20.
Beitner H., Hammer H., Olsson AG, Thyresson N.: Prostaglandin E, treatment of leg ulcers caused by venous or arterial incompetence . Acta Derm Venereol60:425, 1980.
21.
Pardy BJ, Lewis JD, Eastcott Hhg: Preliminary experience with prostaglandins E, and I2 in peripheral vascular disease. Surgery88:826, 1980.
22.
Ambrus JL, Taheri P., Killion, Donaldson G: Clinical experience with prostaglandin E, in the treatment of arteriosclerosis obliterans. A preliminary report. J Med13(5&6): 1, 1982.
23.
Taheri SA, Ambrus L.: Clinical trial in treatment of severe arteriosclerosis of the lower extremities with prostaglandin E,. (In press)Angiology, 1983.
24.
Ambrus JL, Back N., Mihalyi E., Ambrus CM: Quantitative method for the in vivo testing of fibrinolytic agents: Effects of intravenous trypsin on radioactive thrombi and emboli. Circulation Res4:430, 1956.
25.
Ambrus JL, Ambrus CM, Back N., et al: Clinical and experimental studies on fibrinolytic enzymes. Ann NY Acad Sci68:97, 1957.
26.
Back N., Ambrus JL, Simpson CL, Shulman S.: Study on the effects of streptokinase-activated plasmin (fibrinolysin) on clots in various stages of organization. J Clin Invest37:864, 1958.
27.
Ambrus JL, Ambrus CM, Sokal JE, et al: Clinical pharmacology of various types of fibrinolytic enzyme preparations. Am J Cardiol6:462, 1960.
28.
Ambrus CM, Weintraub DH, Dunphy D., et al: Studies on hyaline membrane disease I. The fibrinolysin system in pathogenesis and therapy. Pediatrics32: 10, 1963.
29.
Ambrus CM, Ambrus JL, Choi TS, et al: The fibrinolysin system and its relationship to disease in the newborn. Am J Ped Hem/Oncol1(3):251-260, 1979.
30.
Ambrus CM, Ambrus JL, Courey NG, et al: Inhibitors of fibrinolysis in diabetic children, mothers and their newborn. Am J Hematol7:245-254, 1979.
31.
Snedecor GW, Cochran WG: Statistical Methods. Sixth Edition. Iowa State Univ Press, 1968, p. 126.
32.
Ambrus JL, Ambrus CM, Taheri SA, et al: Red Cell deformability and platelet aggregation in patients with chronic obstructive arterial disease. Study of therapeutic approaches . Angiology (In press) 1983.
